As one of the largest therapy markets in oncology, driven by a high incidence and long treatment durations, the treatment of metastatic HR+/HER2– breast cancer remains commercially lucrative for drug developers. Premium-priced established drugs—Pfizer’s Ibrance and Novartis’s Afinitor—face competition from newly launched agents—Novartis’s Kisqali, Eli Lilly’s Verzenio, and AstraZeneca’s Lynparza—as well as three new oral therapies launching by 2020. Facing escalating drug costs and tightening healthcare budgets, surveyed U.S. payers indicated that new drugs will face reimbursement challenges if they do not prove cost-effectiveor offer efficacy/safety superior tothat of existing therapies. Understanding the market access drivers that are most important to payers and oncologists is essential to maximizing a drug’s market uptake.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
Markets covered: United States
Key companies: AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche, Syndax Pharmaceuticals
Key drugs: Ibrance, Afinitor, Kisqali, Verzenio, Lynparza, Faslodex, Letrozole, Anastrozole, Exemestane